Further Expansion of the Business Foundation in China

「Although orthokeratology-related sales expanded globally, they decreased by ¥350 million due to the effects of economic stagnation and intensifying competition in China.」

「In China, we worked to strengthen sales of orthokeratology lenses and the care products used with them, but the orthokeratology-related market has stagnated due to lower consumer purchasing power amid economic stagnation and the emergence of substitutes. In addition, competition from other companies has become particularly intense in care products.」

「In China, we worked to strengthen sales of orthokeratology lenses and care products, but growth in the orthokeratology-related market has stagnated due to lower consumer purchasing power amid economic stagnation and the emergence of substitutes. In addition, competition from other companies has become particularly intense in care products.」

「Following the first quarter, we continued promotional support for sales channels in China and sought to raise awareness through exhibitions at academic conferences, thereby strengthening sales of orthokeratology-related products.」

「In the region, amid a competitive environment in which the number of competitors is also increasing, our main policy is to strengthen sales of orthokeratology lenses and care products. We are pursuing initiatives to expand sales, including strengthening our sales organization and holding new product presentations for healthcare professionals and distributors in major cities.」

「In China, consumption of contact lens-related products showed signs of recovery as the impact of COVID-19 eased. In the region, our main policy was to strengthen sales of orthokeratology lenses and care products, and we launched our group's second orthokeratology lens product, Menicon Z Night. We are pursuing initiatives to expand sales, including holding new product presentations for healthcare professionals and distributors in major cities.」

「In the region, our main policy was to strengthen sales of orthokeratology lens-related products. In addition to working with distributors to expand sales, we proceeded with preparations to launch our group's second orthokeratology lens product in the Chinese market, Menicon Z Night.」

「In Asia, sales of orthokeratology lenses and care products continued to perform solidly, driven particularly by demand in the Chinese market. We also proceeded with preparations for further market expansion, including obtaining approval for the new orthokeratology lens Menicon Z Night.」

「In China, sales and logistics operations were constrained by the impact of the zero-COVID policy, particularly in urban areas, but we pursued sales activities while implementing infection-control measures under those conditions. As a result, sales of our core products, orthokeratology lenses and care products, continued to perform solidly.」

「In addition, we obtained approval for the medical device registration of our group's second orthokeratology lens product in the Chinese market, Menicon Z Night. We are preparing for its market launch.」

「In China, sales activities were affected in some regions by restrictions related to COVID-19, but we worked to strengthen sales while implementing infection-control measures under those conditions. Our core products, orthokeratology lenses and care products, continued to perform solidly. We also worked to strengthen our production and supply system in anticipation of stable supply and future demand.」

「In the Asian business, centered on China, demand for orthokeratology lenses and care products, supported by their high quality and the strength of Japanese brands, remained strong. Synergies with the Itabashi Boeki Group, made a wholly owned subsidiary in January 2021, were realized throughout the year and contributed to business growth. Sales increased 101.1% year on year, becoming a source of growth for the group as a whole.」

「During the current quarter, sales by the Itabashi Boeki Group, which was made a wholly owned subsidiary in the previous consolidated fiscal year, remained strong, and sales of both orthokeratology lenses and care products progressed steadily.」

「During the current quarter, the sales network of the Itabashi Boeki Group, which was made a wholly owned subsidiary in the previous consolidated fiscal year, made a significant contribution to the increase in sales, and sales of both orthokeratology lenses and care products progressed steadily.」

「In Asia, particularly China, sales of orthokeratology lenses and contact lens care products grew significantly, increasing 57.3% year on year. On the sales side, Itabashi Boeki Co., Ltd. was made a wholly owned subsidiary in January 2021, primarily to strengthen sales capabilities in China, giving the company a sales network for future market expansion. On the production side, a new local company was established in China as a new plant for Alpha Corporation to meet further growth in future demand for orthokeratology lenses, and preparations for commencing operations are under way.」

「In the Chinese market, we entered into a share transfer agreement to make Itabashi Boeki Co., Ltd. a wholly owned subsidiary in order to strengthen our sales network for the expanding orthokeratology lens market and other markets. In addition, Alpha Corporation, which manufactures orthokeratology lenses for our group, established a local company in China with the aim of starting mass production in 2024 to meet growing demand.」

「In the Chinese market, the impact of COVID-19 subsided, and sales of orthokeratology lenses and other products remained solid.」

「In Asia, in June, we acquired an additional interest in 温州欣視界科技有限公司, making it a wholly owned subsidiary. Going forward, we will work to further expand our sales platform with the support of our technology.」

「During the third quarter of the current fiscal year, we acquired an additional interest in 温州欣視界科技有限公司, excluding it from equity-method affiliates and including it within the scope of consolidation.」

「In Asia, sales of orthokeratology lenses and contact lens care products have remained strong in China, and we will continue to promote sales activities.」

「In Asia, sales of orthokeratology lenses and contact lens care products have remained strong in China, and we will continue to promote sales activities.」

「In addition, we launched China's first scleral lens and are contributing to the development of ophthalmic care.」

「In addition, sales in China of orthokeratology lenses and care products for rigid contact lenses, including orthokeratology lenses, have remained solid.」

「In Asia, we are focusing on sales of orthokeratology lenses in China and opened a contact lens training center in the Republic of the Union of Myanmar in May for physicians and optometrists.」

「In Asia, particularly China, the orthokeratology lens market is growing significantly, and sales of care products have remained strong alongside this expansion. We are working to expand our business platform in China.」

「In Asia, sales of care products for China are strong, and we are also working to expand our business platform in China through sales of orthokeratology lenses.」

「In Asia, we are working to expand our business platform in China through sales of orthokeratology lenses.」

「In China, we will seek to expand the business, centered on specialty orthokeratology lenses and care products.」

「In Asia, sales of orthokeratology lenses and contact lens care products have remained strong, particularly in China.」

「In China, sales of orthokeratology lenses, which correct myopia when worn during sleep, have been expanding, and sales of contact lens care products have also remained strong in line with product penetration.」

「In addition, in June, we made Alpha Corporation a subsidiary and will work to further expand our business platform in China by selling orthokeratology lenses, the company's strength, which correct myopia when worn during sleep.」